Analyst Expectations for Ascendis Pharma's Future
Portfolio Pulse from Benzinga Insights
Analysts have provided a mix of somewhat bullish and indifferent ratings for Ascendis Pharma (NASDAQ:ASND) in the last quarter. The average 12-month price target for the company is $130.46, with a high of $187.00 and a low of $89.00. This average price target has increased by 0.45% over the past month.
July 24, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ascendis Pharma has received a mix of somewhat bullish and indifferent ratings from analysts. The average 12-month price target is $130.46, which has increased by 0.45% over the past month.
The mixed analyst ratings indicate uncertainty about the company's future performance. However, the increase in the average price target suggests a positive outlook. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100